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Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely
under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this
article, we provide an overview of the current understanding of the genetics of clozapine-associated
agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neu-
tropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and
SLCO1B3/SLCO1B7. We describe recent indings relating to the Duffy-null genotype and its association
with benign neutropenia in individuals with African ancestry. Further advances will come from sequenc-
ing studies, large, cross-population studies and in understanding the molecular mechanisms underlying
these associations.
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Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia (TRS), one of the most disabling
forms of mental illness characterized by a failure to respond to at least two antipsychotic trials of sufficient dose
and duration [1–4]. Nonetheless, clozapine’s use has been limited by the potential for adverse effects and it remains
widely under prescribed [5]. Of particular importance is the rare, but potentially fatal, hematological side effect of
agranulocytosis: a deficiency of neutrophils (a type of granulocytic white blood cell) to levels below 500/mm3 that
renders the person vulnerable to infections. Neutropenia is a less severe form characterized by neutrophil levels
falling below 1500/mm3. The cumulative prevalence of agranulocytosis and neutropenia in those taking clozapine
is approximately 0.9 and 3.8%, respectively, and the peak incidence is one month after exposure to clozapine
treatment [6–9].
The occurrence of agranulocytosis led to clozapine being withdrawn in the 1970s after reports of associated
fatalities in Finland [10,11]. However, two landmark clinical trails [1,12] demonstrated clozapine’s therapeutic supe-
riority over chlorpromazine in patients with TRS and led to its reintroduction in the 1990s. In most countries,
a condition of clozapine’s licensing was mandatory hematological monitoring to facilitate the early detection of
neutropenia and thus prevent agranulocytosis. If neutropenia is identified in the UK, clozapine treatment is im-
mediately discontinued and usually hematological parameters will subsequently normalize. However, this frequent
hematological monitoring limits the acceptability of clozapine to patients and poses an additional obstacle to
clinician prescribing [13].
The causes of clozapine-induced agranulocytosis (CIA) and neutropenia (CIN) remain unclear although a
genetic contribution has been established [14–16]. The identification of genetic factors that increase susceptibility for
agranulocytosis and neutropenia has received substantial interest as, in addition to providing etiological insights,
a sensitive and reliable predictor could conceivably be used to identify patients most at risk. Furthermore, for
those at low risk there could be a reduced need of regular monitoring, lessening the burden of testing on patients
and services and potentially broadening the availability of clozapine. In this article, we provide an overview of
the current understanding of the genetics of CIA and CIN. There have been several excellent reviews examining
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previous candidate gene studies [17–19], and thus the focus of this article is to describe the advances made from
recent large-scale genomic studies, discuss the current challenges of this field and provide an indication of its future
direction.
Theoretical mechanisms
The mechanism by which clozapine induces agranulocytosis and neutropenia is still not well understood [20,21].
There is evidence indicating it may be caused by the bioactivation of clozapine or a stable metabolite of clozapine
to a chemically reactive nitrenium ion [20,22,23], which has been shown to cause dose-dependent apoptosis to
neutrophils at therapeutic levels of clozapine [24,25] as well as toxicity to stromal cells, the precursors of neutrophils
in bone marrow [26]. The dose-dependent effect of the nitrenium ion suggests that metabolism, bioavailability or
other factors relating to pharmacokinetics could be related to CIA and CIN, a hypothesis supported by recent
association of genetic variants in the hepatic transporter gene SLCO1B3. However, the relationship between
clozapine dose and agranulocytosis remains unclear [27]. Neutrophils themselves can generate hypochlorous acid
via the NADPH/myeloperoxidase (MPO) pathway, which is capable of oxidizing clozapine to reactive metabolites
that covalently bind to neutrophils [23,28,29]. The binding of these reactive metabolites could in turn lead to
agranulocytosis or neutropenia via direct toxicity or by initiating an immune mechanism, or both. An immune
mechanism has long been hypothesized since a number of the characteristics of CIA mirror immune-mediated
reactions including its initial timing, and the fact that it can occur more quickly and severely upon rechallenge
with clozapine. The association of HLA-B and HLA-DQB1 variants from genetic association studies has also added
support for an immune-related mechanism [14,15].
Genetic association studies of clozapine-associated agranulocytosis & neutropenia
The possibility of a genetic contribution to CIA was highlighted from an early stage given the observation that the
incidence in Finland was 20-times higher than other European countries where the drug was widely prescribed [11]. A
six-generation pedigree analysis in the 1970s failed to identify any significant genetic kinship between the affected
patients in Finland, indicating that a single gene following Mendelian inheritance patterns was unlikely to be
responsible [30,31]. There have been reports of concordance of CIA in monozygotic twins [32,33], although no study
to date has formally assessed heritability. Until recently, the majority of genetic association studies have focused
on candidate genes from the human leukocyte antigen (HLA) system, which are involved in immune response.
The application of modern genomic approaches has confirmed that there is a genetic component to CIA and CIN
and that the genetic aetiology is complex, likely involving several genes. In this review, we briefly describe previous
candidate gene studies, summarize recent genome-wide association studies (GWAS) and exome sequencing studies,
and discuss the evidence for specific genetic variants that have been implicated in CIA and CIN.
Candidate gene studies
HLA genes located in the MHC on chromosome 6 (6p21.31-32) encode proteins that are responsible for regulating
the immune system and were thus hypothesized to be involved in CIA [17]. The first case–control study in 1990
by Lieberman et al. in six CIA cases and 25 clozapine-treated controls identified an association with HLA-B38 [34].
The association was also reported in further studies from the same research group [35,36]. However, independent
studies with similarly sized samples reported inconsistent findings for the association of HLA-B38 with CIA [37–40].
Typing of class II alleles by Yunis et al. revealed associations with a number of HLA allele markers in HLA-DRB1,
HLA-DQB1, HLA-DQA1 and HLA-DR [36], most of which have not been independently replicated.
More consistent findings came from the role of HLA-DQB1 in CIA. The HLA marker DQB1*0201 was reported
to be overrepresented in CIA cases in studies by Amar et al. and Dettling et al. [38–40]. A candidate study of 74
genes in 2011 by Athanasiou et al. in 33 CIA cases and 54 controls from the USA, Russia and South Africa found
associations for variants within five genes: HLA-DQB1, HLA-C, HLA-DRD1, NTSR1 and CSF2RB [15]. Using a
previously reported replication sample of 49 CIA cases and 79 controls [39–41], they found evidence for an association
with HLA-DQB1 6672G>C (OR: 16.9; 95% CI: 3.57–109) that was present in 21.5% of the combined cases
and 1.6% of combined controls [15]. The sensitivity and specificity of HLA-DQB1 6672G>C in the combined
sample was 21.5 and 98.4%, respectively. On the basis of this study, HLA-DQB1 6672G>C was marketed as a
predictive genetic test but its low sensitivity limited its clinical utility and it has now been withdrawn due to the
low uptake [17].
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One research group hypothesized that the association of different HLA types in Ashkenazi Jewish and non-Jewish
CIA patients could be caused by the linkage disequilibrium (LD) of a common non-HLA genetic marker in the
MHC [42]. Associations were reported in regard to HSP-70 genes [43] and TNF microsatellites [42,44], but these
findings are yet to be independently replicated and to date there is little evidence to suggest that these genes account
for the association of HLA genes with CIA.
Non-immune mediated hypotheses prompted other candidate gene studies. Because neutrophils can generate
hypochlorous acid via the NADPH/MPO pathway, which is capable of oxidizing clozapine to reactive metabolites
such as a nitrenium ion, there have been studies investigating the role of polymorphisms that alter MPO and
NADPH activity. These studies have not yielded consistent findings [45,46]. However, continuing this hypothesis that
a defective oxidative mechanism leads to the formation of reactive metabolites and consequently CIA, Ostrousky et
al. found a significant association of polymorphisms in NQO2 in 18 CIA cases and 80 clozapine-treated controls [47].
A recent candidate study also found a significant association of the NQO2 1541AA polymorphism in 31 CIA cases
compared with 241 clozapine-treated controls [48]. Lastly, there have been negative studies published investigating
the role polymorphisms in leukocyte Fcγ receptors [49] and CYP2D6, the primary gene involved in clozapine
metabolism [45].
Although there have been many candidate studies, the rare incidence of CIA has limited the availability of suitable
patients and thus studies have been substantially underpowered [50]. Furthermore, there has been a considerable
overlap between study samples, with the majority of candidate studies coming from four or five research groups. It
has become clear in the field of schizophrenia genetics that candidate gene studies have not yielded robust insights
into disease etiology given the limited knowledge of underlying mechanisms [51]. The same limitations of candidate
gene approaches could be leveled at studies in CIA, although in contrast there has been a consistent association
demonstrated for one immune locus in particular, HLA-DQB1.
Large-scale genomic studies of clozapine-associated neutropenia
Recent advances in the field of pharmacogenomics have come from large-scale genetic association studies using
modern techniques such as GWAS and exome sequencing [14,16,52,53]. GWAS is a hypothesis-free approach to
investigating the contribution of common SNPs to traits or disease. GWAS genotyping arrays rely on an informative
backbone of tag SNPs that capture most of the common genetic variation in the genome, and have made large-
scale whole-genome genotyping affordable [54]. Given the rarity of CIA, recent studies have also investigated the
contribution of large, rare copy number variation (CNVs), and protein-coding variants via whole exome sequencing
or exome arrays. It is of note that recent studies have selected a broader neutropenia phenotype, not restricted to
agranulocytosis. This has been a pragmatic strategy given the recent rarity of agranulocytosis due to the success of
monitoring systems, and this approach relies on the assumption that the development of neutropenia whilst taking
clozapine serves as a proxy (or premonitory phase) of agranulocytosis.
The first whole exome sequencing study by Tiwari et al. in 2013 was in 24 Finnish cases with CIN (absolute
neutrophil count [ANC] < 1500 cells/mm3) and 24 age- and sex-matched controls, and did not identify any rare,
functional variants that were significantly associated after correction for multiple testing [52].
In 2014, the Clozapine-Induced Agranulocytosis Consortium (CIAC) published a comprehensive genetic analysis
including GWAS, whole exome sequencing, CNVs and imputed HLA alleles in up to 163 cases with CIN (ANC
< 1000 cells/mm3), 249 clozapine-exposed controls without neutropenia and 7970 unexposed controls [14]. They
found two amino acid polymorphisms in the MHC that were independently and significantly associated with CIN
at the genome-wide significance level of p < 5 × 10-8: HLA-DQB1 (126Q) and HLA-B (158T) [14]. It should be
noted the sample was not independent of samples used in earlier candidate studies that reported associations with
HLA-DQB1 and HLA-B [15,37].
In 2016, we published a study consisting of GWAS, exome array, CNV and imputed HLA allele analyses in
the CLOZUK sample of 66 CIN cases (ANC < 1500 cells/mm3) and 5583 controls who were all treated with
clozapine for a minimum of a year without developing ANC< 2000 cells/mm3, and combined associated variants
in a meta-analysis with the CIAC study [16]. The discovery GWAS analysis identified two intronic SNPs that were
significantly associated with CIN, but were not replicated in the CIAC sample. More promising insights came from
the GWAS meta-analysis; a genome-wide significant association with CIN was found for rs149104283, an intronic
SNP to transcripts of SLCO1B3 and SLCO1B7 [16]. The CLOZUK study also found that although no single rare
variant from the exome array was associated with CIN, gene-based analyses yielded association for two genes:
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Table 1. Genetic risk variants associated with clozapine-induced agranulocytosis/neutropenia from large-scale common
and rare variant association studies.
Gene Variant Effect size Phenotype Populations Evidence from
candidate studies
Association studies
HLA-DQB1 HLA-DQB1 (126Q)
HLA-DQB1 6672GC
HLA-DQB1*05:02
5.2-16.9 CIA & CIN White European,
USA, Russia and South
Africa, Israeli (Jewish
and non-Jewish)
Athanasiou
et al. [15]†
Goldstein et al. [14]†
Legge et al. [16]
HLA-B HLA-B (158T)
HLA-B38/B39/B67
3.3 CIA & CIN White European,
USA, Russia and South
Africa, Israeli (Jewish
and non-Jewish)
Lieberman et al. [34]†
Yunis et al. [35,36]†
Valevski et al. [37]†
Amar et al. [38] (NS)
Dettling et al. [39,40]
(NS)
Goldstein et al. [14]†
HLA-B*59:01 6.3-15.8 CIN Japanese Saito et al. [53]
SLCO1B3/7 rs149104283 4.32 CIN White European Saito et al. [64] (NS) Legge et al. [16]
ACKR1 rs2814778 20.36 CIN African ancestry Legge &
Pardin˜as et al. [55]
Genetic risk variants associated with CIN and CIA from large-scale common and rare variant association studies. Variants were only included that had evidence of association from
non-candidate genetic studies. Columns include: gene, variant name, effect size of genetic variant, phenotype the genetic variant has been associated with, populations used in studies,
candidate studies and association studies. Amino acid polymorphism HLA-DQB1 (126Q), HLA-DQB1 6672GC and HLA-DQB1*05:02 are all in strong LD and likely to convey same
association signal. Similarly for HLA-B (158T) and HLA-B38. Effect sizes are estimated from large-scale association studies only.
†Studies with overlapping cases.
CIA: Clozapine-induced agranulocytosis, CIN: Clozapine-induced neutropenia; HLA: Human leukocyte antigen; LD: Linkage disequilibrium.
UBAP2 and STARD9 [16]. Furthermore, direct genotyping in 60 cases and 305 controls found an independent
replication of the previously associated variant HLA-DQB1 6672G>C [15].
Saito et al. reported a further GWAS of 50 cases with CIN (ANC< 1500 cells/mm3) and 380 clozapine-exposed
controls without neutropenia and 2905 unexposed controls from the Japanese population [53]. As they detected a
genome-wide significant MHC signal from the GWAS analyses, they conducted classical HLA typing and found
a significant association of HLA-B*59:01 with CIN in comparison to both clozapine-exposed and unexposed
controls.
In the most recent study, we conducted a GWAS analysis of lowest ANC during clozapine treatment (as opposed
to neutropenia case vs controls) in 552 individuals from the UK with robustly inferred African ancestry [55]. Two
genome-wide significant loci were identified, of which the most significant locus was indexed by rs2814778, a
regulatory variant in ACKR1 that has previously been associated with lower neutrophil counts in individuals of
African ancestry, and is thought to be causal for benign ethnic neutropenia (BEN).
The strength of the evidence and clinical relevance for the key genetic variants identified from large-scale genetic
studies investigating CIN is discussed below.
Risk variants for clozapine-associated neutropenia
Table 1 details the genetic risk variants associated with CIN and CIA from large-scale common and rare variant
association studies.
HLA-DQB1
There is now considerable support for the role of variants within HLA-DQB1 in CIN and CIA. The association of
this gene was initially identified by candidate gene studies [15,36,38–40] and the imputed amino acid polymorphism
HLA-DQB1 (126Q) was the most significantly associated variant from the CIAC study [14]. HLA-DQB1 (126Q) is
in strong LD with HLA-DQB1 6672G>C, the variant implicated in the candidate study by Athanasiou et al. [15].
Although the CIAC study includes cases from the earlier candidate studies that implicated HLA-DQB1 [15,37,41],
the CLOZUK study provided further replication in an independent sample for the association of HLA-DQB1
6672G>C [16]. Therefore, this finding represents the most robustly associated variant for CIN and CIA. However,
the causal variants and biological mechanisms of how this association leads to CIN are yet to be resolved. These
findings are limited to individuals of European ancestry and so it is currently unknown whether variants in
HLA-DQB1 also increase risk in other populations.
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HLA-B
There is increasing evidence for the role of variants in HLA-B in CIN from large-scale genomic studies. The imputed
amino acid polymorphism HLA-B (158T) was significantly associated with CIN in the CIAC study, independent
of HLA-DQB1 (126Q), and primarily driven by the association in individuals of Ashkenazi Jewish ancestry [14].
The amino acid change at HLA-B (158T) corresponds to HLA-B38, which has also been implicated in previous
candidate gene studies [34,37], although some of these samples overlap with the CIAC study and there have also
been negative reports [34–40]. Further evidence for the role of HLA-B has come from Saito et al. [53], who found a
significant association of HLA-B*59:01 with CIN in the Japanese population. HLA-B*59:01 is a rare (∼1–2%)
variant in Japanese and east Asian populations and reference datasets indicate that it is monomorphic in other
Caucasian and African populations. Saito et al. report that it is not compatible with the amino acid polymorphism
HLA-B (158T) reported by Goldstein et al. Nonetheless, integrating association signals from different populations
might help in the discovery of causative variants by leveraging on differential LD patterns between populations. As
with HLA-DQB1, it is currently unclear how the risk variants from HLA-B lead to CIN, although it is presumed
to be through an immune-related mechanism.
SLCO1B3/SLCO1B7
The meta-analysis by Legge et al. of CLOZUK and CIAC identified a genome-wide significant association for a
genetic locus indexed by rs149104283 (odds ratio [OR]: 4.32), an intronic SNP to transcripts of hepatic transporter
genes SLCO1B3 and SLCO1B7 [16]. rs149104283 was present in 7.37% of CIN cases versus 1.52% of controls
in the CLOZUK sample and 4.20% of CIN cases versus 1.67% of controls in the CIAC sample. This finding
indicates a possible pharmacokinetic mechanism for CIN as the associated region encodes for liver-specific organic
anion-transporter polypeptides that facilitate the uptake of drugs such as clozapine from the portal vein into
hepatocytes, where it is subsequently metabolized or excreted [56,57]. Polymorphisms from these genes have also
been implicated in adverse reactions of other drugs such as docetaxel-induced neutropenia [58–61] and simvastatin-
induced myopathy [62,63]. Replication of rs149104283 in independent samples and further functional studies are
required to determine if these hepatic transporter genes do in fact influence the uptake or metabolism of clozapine
and how this consequently leads to neutropenia and agranulocytosis.
Saito et al. reported a lack of replication of this signal in their sample of 50 cases with CIN and 2905 healthy
control subjects from the Japanese population [64]. However, the index SNP from Legge et al. rs149104283,
was monomorphic in their Japanese sample and the SNP they used for replication (rs11045434) was in linkage
equilibrium with rs149104283 (R2 = 0, estimated from LDlink for all populations [65]). When the index SNP is
not available, valid replication candidate SNPs must be both in high LD and within the local genomic region [66].
Thus, the use of this SNP for replication is inappropriate and does not provide evidence either for or against
the association of rs149104283. Saito et al. selected this SNP as it was in the genomic region of SLCO1C1 and
upstream of SLCO1B3 and showed a modest association with clozapine-associated neutropenia. It is possible that
the associated regions from these two studies differ due to population differences but impact onto a common
mechanism and further studies are required to investigate this possibility.
There has been a recent interest in a pharmacokinetic mechanism via polymorphisms within ABCB1, the P-
glycoprotein transporter gene responsible for the excretion of major clozapine metabolites, as there is evidence they
effect clozapine plasma levels [67,68]. However, there is very limited evidence to date to suggest they cause CIN or
CIA [48,69].
ACKR1
In the first genetic association study of neutrophil counts during clozapine treatment in UK individuals with African
ancestry, we identified a strong association of a locus on chromosome 1 attributable to rs2814778 (p = 4.21× 10-21),
a regulatory variant in ACKR1 [55]. The CC genotype at rs2814778 is also known as the Duffy-null genotype and is
rare in most non-African populations [70]. However, in those of African ancestry, it has been robustly associated with
neutrophil counts [71–74] and is also considered to be the cause of BEN [75], an hereditary condition characterized
by low neutrophil counts which occurs in 25–50% of individuals with African or Middle Eastern ancestry [75–78].
In those with African ancestry, individuals with the Duffy-null genotype were substantially more likely to develop
neutropenia whilst taking clozapine (OR: 20.36), indicating that clozapine-associated neutrophil levels in people
of African ancestry are often a result of BEN rather than an adverse drug reaction. This finding indicates that
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Table 2. Sensitivity and speciicity of genetic variants for clozapine-induced agranulocytosis/neutropenia.
Genetic variants Sensitivity (%) Speciicity (%) PPV (%) NPV (%) Study [Ref.]
HLA-DQB1 6672GC 21.5 98.4 5.1 99.7 Athanasiou et al. [15]
HLA-DQB1 (126Q) and
HLA-B (158T)
36.0 89.0 NR NR Goldstein et al. [14]
SLCO1B3/7 rs149104283 10.9 97.6 14.0 96.9 Legge et al. [16]
SLCO1B3/7 rs149104283
and HLA-DQB1 6672 GC
29.2 90.6 9.9 97.3 Legge et al. [16]
HLA-B*59:01 (CIN vs
clozapine control)
24.0 95.3 17.4 96.8 Saito et al. [53]
HLA-B*59:01 (CIA vs
clozapine control)
31.8 95.3 6.4 99.3 Saito et al. [53]
Sensitivity and speciicity of using identiied genetic variants for CIA and CIN as a predictive genetic test. Reported columns include: the genetic risk variant(s) used to predict CIN, sensitivity,
speciicity, PPV, NPV and the study. Values for HLA-B*59:01 variant were also consistent for CIA and CIN versus healthy controls reported by Saito et al. [53].
CIA: Clozapine-induced agranulocytosis, CIN: Clozapine-induced neutropenia; HLA: Human leukocyte antigen; NPV: Negative predictive value; NR: Not reported; PPV: Positive predictive
value.
there may be at least three genetic mechanisms impacting on CIN; those that impact immune reactivity, hepatic
uptake (and potentially subsequent drug toxicity), and genetic factors that cause benign neutropenia unrelated to
clozapine.
Current indications for genetic testing
The genetic variants that have been identified to date for CIA and CIN as an adverse drug reaction (i.e., variants
in HLA-DQB1, HLA-B, and SLCO1B3/SLCO1B7) do not fulfill the criteria for a predictive genetic test [79].
Table 2 details the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of a
potential pharmacogenetic test using these variants to predict CIN. Across all reported variants, sensitivity values
range from 11 to 36%, specificity from 89 to 98%, PPV from 5.1 to 25.9% and NPV from 96.9 to 99.7%.
The highest sensitivity value reported to date was from Goldstein et al. [14] for the combination of HLA-DQB1
(126Q) and HLA-B (158T). Nonetheless, these figures mean that less than half of the individuals who develop
clozapine-associated neutropenia will have any one of the risk variants identified to date. A modeling study by
Verbelen et al. demonstrated that high sensitivity is the critical factor for a successful genetic test for CIA [79].
Indeed, on the basis of the study by Athanasiou et al. [15], HLA-DQB1 6672G>C was marketed as a genetic test
but the low sensitivity (21.5%) limited its clinical utility and it was withdrawn due to the low uptake [17]. Girardin
et al. demonstrated that despite not being suitable for clinical application, a strategy to withdraw monitoring in
those that have neither HLA-DQB1 (126Q) or HLA-B (158T) risk variants, considering the risk is reduced to a
level that is similar to other drugs, genetic testing would still be cost-effective in US settings providing it cost less
than $700 per patient [80].
Recent findings have uncovered the potential for a genetic test to identify those at high risk of benign neutropenia
that is unrelated to clozapine, but nonetheless disrupts treatment. Our study indicates that genotyping of rs2814778
to identify individuals with the Duffy-null genotype has clinical utility as an alternative strategy for the diagnosis
of BEN in individuals with African ancestry, which is currently made by hematology assessment [55]. However,
prior to the implementation of Duffy-null genotype testing, crucial studies are necessary to establish the safety,
practicality and cost-benefits of such a test. Theoretically, individuals with the Duffy-null genotype could have
revised neutrophil thresholds in line with current BEN monitoring procedures for clozapine treatment, provided
they do not show signs of compromised immune function. This ability to prospectively lower neutrophil thresholds
would permit more BEN patients to start clozapine at the lower baseline threshold and also avoid disruption
of treatment for those who discontinue clozapine due to benign neutropenia. Approximately 80% of the UK
population with African ancestry and the 64% of the African–American population in the USA would test positive
for this pharmacogenetic screening test. However, the potential applications extend beyond those of self-reported
African ancestry given rs2814778 is polymorphic in parts of the Middle East, south west Asia and Oceania [70].
Conclusion & future perspective
The application of GWAS and other modern genomic techniques has led to advances in our understanding of the
genetic basis of CIA and CIN. Recent studies have provided evidence for the role of variants in HLA-DQB1, HLA-B
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and SLCO1B3/SLCO1B7 for CIN, and for the Duffy-null genotype on benign neutropenia in individuals with
African ancestry. The latter has potential clinical utility, pending safety studies, as a genetic test to revise clozapine
safety blood-monitoring criteria, raising the realistic prospect of clinically applicable pharmacogenetic testing in
psychiatry. Future challenges will include the refinement of identified genome-wide association loci signals, through
bioinformatic and perhaps sequencing efforts, and characterizing their functional and biological significance. We
also advocate for the inclusion of diverse population samples in future studies particularly given the often greater
burden of TRS in non-European populations. Finally, less than half of the individuals who develop CIN have a
currently identified risk variant and thus further studies are required to determine why the individuals without
these risk variants develop the rare adverse effect.
Recent studies indicate that the genetic etiology of CIN is complex and is likely to involve at least several genes.
At present, it appears unlikely that this rare adverse effect is caused by a rare variant of very large effect, a rare
protein-coding variant or a rare, pathogenic CNV [14,16,52], although the application of whole-genome sequencing
is required to conclude this definitively. Although there is evidence for the role of variants in HLA-DQB1, HLA-B
and SLCO1B3/SLCO1B7, the mechanism through which these variants lead to increased risk of CIN remains
unclear. This is a limitation that applies more generally to GWAS findings in that many of the SNPs detected are
noncoding variants with an unknown impact [81]. Thus, functional follow-up studies are required to determine the
causal SNP(s) and associated biological mechanisms. Improved annotation of these signals together with recent
advances in whole-genome sequencing should provide informative answers in this regard.
An on going challenge for the field will be the relatively rare incidence of CIN and even rarer incidence of CIA,
which limits the availability of suitable patients and thus results in studies having small-sample sizes [50]. This has
a significant impact on statistical power; the CIAC study had 99% power and the CLOZUK discovery sample
80% power to detect an odds ratio greater than 4.0 for alleles with a frequency greater than 0.10. Thus, even the
recent genetic studies of CIN are underpowered to detect associations that do not have a moderate to large effect
size. It is likely that there are causal variants of small effect that have not yet been detected and the field requires
larger samples to determine if this is the case and to characterize the genetic architecture of CIN and CIA. Greater
insights should be gained in the near future from the CRESTAR project, which aims to combines in meta-analysis
all of the available CIN samples.
In order to increase sample sizes, two of the GWAS have used predominantly population controls as opposed
to clozapine-treated or schizophrenia controls [14,53]. In these situations, it is important for any associations to be
confirmed with clozapine-treated controls, as it is possible the variant could be associated with schizophrenia rather
than CIN. Indeed, both of these GWAS found large association peaks around the MHC [14,53], which is also a
predominant feature of schizophrenia GWAS analyses [82].
An important consideration is the use of a neutropenia phenotype as opposed to agranulocytosis in recent studies.
It is possible that neutropenia and agranulocytosis have distinct etiologies [21]. However, agranulocytosis is now very
rare due to the success of the monitoring system, which in many countries such as the UK, triggers discontinuation
of clozapine as a precaution when neutropenia is detected. This means, however, that it is not possible to know
which patients would go on to develop agranulocytosis and who may be experiencing a benign neutropenia. This is
especially important in populations with increased rates of BEN; individuals with the genetic variant for BEN are
20-times more likely to develop neutropenia and have clozapine discontinued [55]. Neutropenia in these individuals
is most likely benign and not an adverse effect of clozapine. Nonetheless, given in the field there are valid concerns
that a more stringent threshold may produce more reliable results, it is important, as most studies have done, to
confirm findings at more severe thresholds.
Historically, most studies of CIN have been performed in populations with European ancestry. This is changing,
with recent studies in the Japanese population [53] and in individuals from the UK with African ancestry [55].
Cross-population studies are vital to determine the generalizability of risk variants or whether effects are population
specific, and perhaps particularly important for the immune and metabolic systems that are highlighted by existing
research. Furthermore, the ability to identify more genetic loci associated with CIN from different populations
should help identify causative variants by leveraging on different LD patterns between populations [83]. However,
failure to replicate associated variants in differing ethnicities and populations can arise for a number of reasons
including that the initial association was a false-positive result, the replication is falsely negative due to study power
or sample differences, or because the variant exerts a population-specific effect, and distinguishing between these is
challenging [83]. A gold standard example of population-specific genetic risk comes from the rare adverse effect of
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Stevens–Johnson syndrome and toxic epidermal necrolysis from carbamazepine that is strongly associated with HLA-
B*1502 in individuals of Asian descent [84] but with HLA-A*3101 in European and Japanese populations [85,86].
In conclusion, recent years have seen important advances in our understanding of the genetic causes of CIN
and CIA. Future developments will come from increasing sample sizes to identify novel risk variants, conducting
cross-population studies, identifying the causal variants and in applying approaches to understanding the molecular
mechanisms underlying these associations. These approaches will be key to the clinical translation of the genetic
risk for CIA.
Executive summary
Theoretical mechanisms
• The mechanism by which clozapine induces neutropenia (CIN) and agranulocytosis (CIA) is still unclear but there
is evidence it is caused by the activation of clozapine to a chemically reactive nitrenium ion, which could lead to
neutropenia via direct toxicity, or by initiating an immune mechanism, or both.
• The association of genetic variants in hepatic transporter genes SLCO1B3 and SLCO1B7 indicates a potential
pharmacokinetic mechanism for CIA and CIN.
• The association of genetic variants in HLA-DQB1 and HLA-B provides support for an immune related mechanism
for CIN.
Genetics of clozapine-associated neutropenia
• Early candidate gene studies have implicated HLA genetic variants from the MHC.
• A whole exome sequencing study and four genome-wide association studies have now been published. Two
genome-wide association studies included populations with European ancestry, the third included a Japanese
population and the fourth investigated neutrophil counts in individuals with African ancestry. These studies have
provided evidence for variants in in HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7 for CIN and evidence for the
Duffy-null genotype in ACKR1 for benign neutropenia during clozapine treatment.
Key risk variants for clozapine-associated neutropenia
• There is now considerable support for the role of the amino acid polymorphism HLA-DQB1 (126Q) and HLA-DQB1
6672G>C (which are in high linkage disequilibrium) in CIN.
• The amino acid change at HLA-B (158T), which corresponds to the previously associated variant HLA-B38, has
been associated with CIN in populations with European ancestry. HLA-B*59:01 has been associated with CIN in
the Japanese population.
• CIN has also been associated with rs149104283 in those of European ancestry, an intronic SNP in hepatic
transporter genes SLCO1B3 and SLCO1B7.
• A strong association with the Duffy-null genotype, a regulatory variant in ACKR1, has been identiied for benign
neutropenia in people with African ancestry.
Current indications for genetic testing
• The genetic variants that have been identiied to date for neutropenia as an adverse drug reaction do not
currently indicate suitability for a predictive genetic test due to low sensitivity.
• Genotyping of rs2814778 (ACKR1) to identify individuals with the Duffy-null genotype in those with African
ancestry offers potential as a pharmacogenetic test to diagnose benign ethnic neutropenia and prospectively
revise clozapine safety blood monitoring criteria.
Conclusion & future perspective
• The genetic aetiology of CIN is complex and is likely to involve variants from several genes including HLA-DQB1,
HLA-B and SLCO1B3/SLCO1B7.
• The Duffy-null genotype causes benign neutropenia, which is often mistaken for CIN, in individuals with African
ancestry.
• Future advances will come from increasing sample sizes to identify novel risk variants, conducting
cross-population studies, identifying causal variants from association signals and in understanding the molecular
mechanisms underlying these associations.
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